Nevertheless, current evidence supports GLP-1 RAs and multi-agonist formulations as highly promising pharmacotherapies that address the complex, multifactorial pathophysiology of MASLD while simultaneously improving cardiometabolic comorbidities, positioning them as cornerstone treatments in the evolving therapeutic landscape for this prevalent and burdensome disease
resM is a carefully designed blend that helps activate your bodys own GLP-1 signaling, without injections or the fatigue that can follow.* Pre-clinical studies showed it boosts natural GLP-1 production by as much as 300%!* resM is packed with a heat-inactivated probiotic, chromium, fenugreek, white mulberry, plus vitamins D3 and B12 to support appetite control, steady healthy blood sugar already in normal range, and immune health - all while helping quiet food cravings.* Its vegan, non-GMO, free of common allergens, and designed for everyday use, even alongside GLP-1 prescriptions or during transitions off medication.* Think of it as a way to restore your natural rhythms and hop off the fatigue cycle.* Learn more about how it can help you today
defense briefs commonly argue intentional misuse and reliance on warnings
A recent analysis utilizing five US national healthcare claims cohorts from 2018 to 2024 simulated the STEP-HFpEF DM (semaglutide) and SUMMIT (tirzepatide) trials to benchmark outcomes and expanded the eligibility criteria to reflect real-world clinical practice
To rule out inferiority, the FDA required CVOTs to show an upper boundary risk ratio of 1.3 (post approval), utilizing a two-sided 95% confidence interval (CI), for major adverse cardiovascular events (MACE) [55]
